Riikka Nissinen

Riikka Nissinen serves as the Global RWE Lead and acting Head of Global Medical Affairs for Innovative Medicines at Orion Corporation since December 2023. Previously, Nissinen spent over a decade at The Janssen Pharmaceutical Companies of Johnson & Johnson, holding various roles including EMEA RWE Strategy Lead, Nordic Medical Advisor, and Associate Director for Global Risk-Benefit Initiatives. Responsibilities encompassed strategic, scientific, and operational leadership in Real World Evidence studies across multiple therapy areas, as well as partnerships with EMEA Marketing and Medical Affairs. Nissinen's career includes significant experience in medical support for global product launches, risk-benefit assessments, and management in gastrointestinal and dermatological fields, beginning with Centocor. Educational qualifications include an MBA from Henley Business School, a PhD in Immunology, and an MSc in Biochemistry, both from the University of Helsinki.